People with MS who are being treated with rituximab are strongly encouraged to receive mRNA SARS-CoV-2 vaccines and booster doses more than 6 months after their last rituximab infusion, researchers reported in JAMA Network Open.
“Treatment with rituximab or other B-cell-depleting therapies has been associated with an increased risk of more severe COVID-19, including death in unvaccinated persons with MS, compared with those treated with several other disease modifying-therapies and the general population without MS,” Jessica B. Smith, MPH, of the department of research and